A peptide is a short chain of amino acids — the same building blocks proteins are made of, just fewer of them. The conventional dividing line sits around fifty amino acids: shorter is a peptide, longer is a protein. The distinction is arbitrary but useful.
Why they're interesting
Your body already uses peptides as signaling molecules. Insulin is a peptide. So is oxytocin, glucagon and the GLP-1 that weight-loss medications mimic. These are not foreign compounds; they are the vocabulary your physiology uses to talk to itself.
That creates a therapeutic opportunity. A synthetic peptide can engage a specific receptor with high selectivity, which often means fewer off-target effects than a small-molecule drug hitting the same pathway.
Why they're complicated
Peptides are fragile. Oral administration exposes them to digestive enzymes designed specifically to break peptide bonds, which is why most require injection. They also have short half-lives, and manufacturing them consistently is harder than making a small molecule.
The evidence tiers
The single most useful thing you can do when evaluating a peptide is to ask which tier it sits in.
Tier one: FDA-approved
Semaglutide, tirzepatide, bremelanotide and others have been through full clinical trials with outcome data and a characterized safety profile. Approval is not a guarantee of benefit for you, but the evidence question is settled.
Tier two: substantial human data, not US-approved
Thymosin alpha-1 is the clearest example — in clinical use in dozens of countries with published randomized trials, but not FDA-approved. The evidence exists; the regulatory pathway simply hasn't been pursued domestically.
Tier three: preclinical and mechanistic
BPC-157 and TB-500 sit here. Animal data is encouraging and the mechanisms are plausible. Controlled human trials are largely absent. Using them is a considered bet, and should be described that way rather than dressed up as established medicine.
Sourcing is a safety issue
The research-chemical market operates outside pharmaceutical quality standards. Independent testing of grey-market peptides has repeatedly found underdosing, wrong compounds and bacterial contamination. Whatever you decide about a compound, the source is a separate and non-negotiable question.
- Require third-party potency and sterility testing by lot.
- Require a licensed compounding pharmacy, not a research supplier.
- Require a clinician who will tell you which tier the evidence is in.
- Treat "not for human consumption" labeling as the disqualifier it is.